More than 2 million people have accessed their personal genetic information through 23andMe. Our Health + Ancestry Service allows individuals to acquire this information from the privacy of their own homes, without medical requisition.
Nearly 30% of consumers who undergo direct-to-consumer (DTC) genetic testing choose to share their reports with healthcare providers to inform conversations about their health.1,2,3 Our Healthcare Professionals community was created to help U.S. providers and their patients navigate genetics together in order to make important informed decisions about prevention, treatment and healthy living.
Join our community to receive important updates about new features and information about upcoming educational programs and engagement opportunities.
At 23andMe, we believe that when consumers engage with their genetics, they are able to play a more active role in their health. We also believe the human genome holds the promise of contributing to major breakthroughs in medical research efforts. We go beyond genetic testing to engage consumers in research with the goal of accelerating therapeutic development. ~85% of our customers consent to participate in research, making 23andMe an important study partner in pioneering research.
The 23andMe Personal Genetic Service provides information and tools for individuals to learn about their DNA.
23andMe researchers and our collaborators make meaningful discoveries using genetic data and survey information.
23andMe Therapeutics strives to use human genetic data to accelerate the discovery of novel treatments.
What causes consumers to pursue DTC genetic testing? Motivations include obtaining health-related information, learning about genetic risk factors, being on the vanguard of a new technology, curiosity in genetics, contributing to research and investigating self-identity.4
For individuals interested in genetic health information, it’s important to note that the 23andMe experience is not intended to be a diagnostic tool. Our objective is not to detect disease, but to deliver genetic information in the most engaging and responsible way. Our Genetic Health Risk and Carrier Status reports may, in certain cases, provide valuable information for clinical management.
Explore our reports to better understand the types of information your patients receive and may share with you.
* The 23andMe PGS test uses qualitative genotyping to detect clinically relevant variants in the genomic DNA of adults from saliva collected using an FDA-cleared collection device (Oragene·DX model OGD-500.001) for the purpose of reporting and interpreting genetic health risks and reporting carrier status. It is not intended to diagnose any disease. The relevance of each report varies based on ethnicity. Each Genetic Health Risk report describes if a person has variants associated with a higher risk of developing a disease, but does not describe a person’s overall risk of developing the disease. These reports are intended to provide genetic information that can be used to inform lifestyle decisions and conversations with healthcare professionals, but are not intended to tell you anything about your current state of health, or to be used to make medical decisions, including whether or not you should take a medication or how much of a medication you should take. Any diagnostic or treatment decisions should be based on testing or other information deemed appropriate by a healthcare professional. Our Carrier Status reports can be used to determine carrier status, but cannot determine if you have two copies of any genetic variant. These carrier reports are not intended to tell you anything about your risk for developing a disease in the future or anything about the health of your fetus, or your newborn child’s risk of developing a particular disease later in life. For Gaucher Disease Type 1, we provide a single report that includes information on both carrier status and genetic health risk. The Late-Onset Alzheimer’s Disease Genetic Health Risk report is indicated for reporting of the ε4 variant in the APOE gene and describes if a person has a variant associated with an increased risk of developing late-onset Alzheimer’s disease. The ε4 variant included in this report is found and has been studied in many ethnicities. Detailed risk estimates have been studied the most in people of European descent. The Parkinson’s Disease Genetic Health Risk report (i) is indicated for reporting of the G2019S variant in the LRRK2 gene, and the N370S variant in the GBA gene, (ii) describes if a person has variants associated with an increased risk of developing Parkinson’s disease and (iii) is most relevant for people of European, Ashkenazi Jewish and North African Berber descent. The Hereditary Thrombophilia Genetic Health Risk report (i) is indicated for reporting of the Factor V Leiden variant in the F5 gene, and the Prothrombin G20210A variant in the F2 gene, (ii) describes if a person has variants associated with a higher risk of developing harmful blood clots and (iii) is most relevant for people of European descent. The Cystic Fibrosis Carrier Status test is indicated for the detection of 28 variants in the CFTR gene and is most relevant for people of Ashkenazi Jewish, European and Hispanic/Latino descent. The Sickle Cell Anemia Carrier Status test is indicated for the detection of the HbS variant in the HBB gene and is most relevant for people of African descent. The Carrier Status tests related to hereditary hearing loss consist of two tests — one indicated for the detection of two variants in the GJB2 gene, which is most relevant for people of Ashkenazi Jewish and European descent, and one indicated for the detection of six variants in the SLC26A4 gene.